308 related articles for article (PubMed ID: 3159794)
1. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
Nagarkatti M; Kaplan AM
J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.
Nagarkatti M; Toney DM; Nagarkatti PS
Cancer Res; 1989 Dec; 49(23):6587-92. PubMed ID: 2573418
[TBL] [Abstract][Full Text] [Related]
3. Characterization of T lymphocyte clones isolated from BCNU-cured LSA mice.
Selvan RS; Nagarkatti PS; Nagarkatti M
Int J Cell Cloning; 1991 Nov; 9(6):594-605. PubMed ID: 1770232
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
Nagarkatti M; Nagarkatti PS; Kaplan AM
Cancer Immunol Immunother; 1988; 27(1):38-46. PubMed ID: 3260820
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
Chow KP; Battisto JR
J Immunol; 1988 Feb; 140(4):1005-13. PubMed ID: 2963857
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
7. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of mice bearing syngeneic tumors with 1,3-bis (2-chloroethyl)-1-nitrosourea is effective only in normal, but not in irradiated or nude, mice: role of L3T4+ (CD4+) and Lyt-2+ (CD8+) T cells.
Nagarkatti M; Seth A; Nagarkatti PS
Cell Immunol; 1988 Sep; 115(2):383-92. PubMed ID: 3261638
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
Nagarkatti M; Clary SR; Nagarkatti PS
J Immunol; 1990 Jun; 144(12):4898-905. PubMed ID: 1972170
[TBL] [Abstract][Full Text] [Related]
10. Suppressor T cells, distinct from "veto cells," are induced by alloantigen priming and mediate transferable suppression of cytotoxic T lymphocyte responses in vivo.
Owens T; Crispe IN
J Immunol; 1985 Nov; 135(5):2984-9. PubMed ID: 2413108
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
12. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
Roberts LK
J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
[TBL] [Abstract][Full Text] [Related]
14. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
15. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
16. Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
Sensi M; Bergomi M; Formelli F; Parmiani G
Int J Cancer; 1990 Dec; 46(6):1088-94. PubMed ID: 2249896
[TBL] [Abstract][Full Text] [Related]
17. T cells from naive mice suppress the in vitro cytotoxic response against endogenous Gross virus-induced tumor cells.
Tilkin AF; Gomard E; Begue B; Levy JP
J Immunol; 1984 Jan; 132(1):520-6. PubMed ID: 6228582
[TBL] [Abstract][Full Text] [Related]
18. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
Schmid DS; Rouse BT
J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
[TBL] [Abstract][Full Text] [Related]
19. Lyt-2+ suppressor T cells are resistant to anti-Lyt-2 antibody blocking.
Hollander N
J Immunol; 1985 Apr; 134(4):2205-8. PubMed ID: 2579133
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
